JP2015530989A5 - - Google Patents

Download PDF

Info

Publication number
JP2015530989A5
JP2015530989A5 JP2015526762A JP2015526762A JP2015530989A5 JP 2015530989 A5 JP2015530989 A5 JP 2015530989A5 JP 2015526762 A JP2015526762 A JP 2015526762A JP 2015526762 A JP2015526762 A JP 2015526762A JP 2015530989 A5 JP2015530989 A5 JP 2015530989A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
hvr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015526762A
Other languages
English (en)
Japanese (ja)
Other versions
JP6352264B2 (ja
JP2015530989A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/054664 external-priority patent/WO2014028446A1/en
Publication of JP2015530989A publication Critical patent/JP2015530989A/ja
Publication of JP2015530989A5 publication Critical patent/JP2015530989A5/ja
Application granted granted Critical
Publication of JP6352264B2 publication Critical patent/JP6352264B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2015526762A 2012-08-13 2013-08-13 抗ｊａｇｇｅｄ抗体および使用方法 Active JP6352264B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261682640P 2012-08-13 2012-08-13
US61/682,640 2012-08-13
US201361784332P 2013-03-14 2013-03-14
US61/784,332 2013-03-14
PCT/US2013/054664 WO2014028446A1 (en) 2012-08-13 2013-08-13 Anti-jagged anitbodies and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018082543A Division JP6619047B2 (ja) 2012-08-13 2018-04-23 抗ｊａｇｇｅｄ抗体および使用方法

Publications (3)

Publication Number Publication Date
JP2015530989A JP2015530989A (ja) 2015-10-29
JP2015530989A5 true JP2015530989A5 (enExample) 2017-09-21
JP6352264B2 JP6352264B2 (ja) 2018-07-04

Family

ID=49004047

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015526762A Active JP6352264B2 (ja) 2012-08-13 2013-08-13 抗ｊａｇｇｅｄ抗体および使用方法
JP2018082543A Active JP6619047B2 (ja) 2012-08-13 2018-04-23 抗ｊａｇｇｅｄ抗体および使用方法
JP2019204815A Active JP7366700B2 (ja) 2012-08-13 2019-11-12 抗ｊａｇｇｅｄ抗体および使用方法
JP2021131076A Withdrawn JP2021191275A (ja) 2012-08-13 2021-08-11 抗ｊａｇｇｅｄ抗体および使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018082543A Active JP6619047B2 (ja) 2012-08-13 2018-04-23 抗ｊａｇｇｅｄ抗体および使用方法
JP2019204815A Active JP7366700B2 (ja) 2012-08-13 2019-11-12 抗ｊａｇｇｅｄ抗体および使用方法
JP2021131076A Withdrawn JP2021191275A (ja) 2012-08-13 2021-08-11 抗ｊａｇｇｅｄ抗体および使用方法

Country Status (10)

Country Link
US (4) US10113002B2 (enExample)
EP (1) EP2882776B1 (enExample)
JP (4) JP6352264B2 (enExample)
KR (2) KR102193080B1 (enExample)
CN (1) CN104520328B (enExample)
BR (1) BR112015003032B1 (enExample)
CA (1) CA2880271C (enExample)
MX (2) MX381841B (enExample)
RU (2) RU2666990C2 (enExample)
WO (1) WO2014028446A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130089562A1 (en) 2011-10-05 2013-04-11 Genenthech, Inc. Methods of treating liver conditions using notch2 antagonists
SG11201408554QA (en) 2012-06-22 2015-02-27 Cytomx Therapeutics Inc Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
RU2666990C2 (ru) 2012-08-13 2018-09-13 Дженентек, Инк. Антитела к jagged и способы их применения
WO2014110506A2 (en) * 2013-01-14 2014-07-17 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
MX2015011444A (es) 2013-03-15 2015-12-16 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
SI3105253T1 (sl) 2014-02-12 2018-10-30 F. Hoffmann-La Roche Ag Protitelesa anti-Jagged1 in načini njihove uporabe
EP3166627A1 (en) 2014-07-11 2017-05-17 Genentech, Inc. Notch pathway inhibition
JOP20190259A1 (ar) * 2017-05-31 2019-10-31 Amgen Inc بروتينات ربط مولد ضد مضادة لـ jagged1

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004924A (en) 1991-12-11 1999-12-21 Imperial Cancer Research Technology, Ltd. Protein sequences of serrate gene products
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20030170636A1 (en) * 2002-03-05 2003-09-11 Isis Pharmaceuticals Inc. Antisense modulation of jagged 2 expression
US20030185829A1 (en) * 2002-03-12 2003-10-02 Erich Koller Jagged 2 inhibitors for inducing apoptosis
US20040101847A1 (en) 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Notch2 expression
CA2496547A1 (en) 2002-08-29 2004-03-11 University Of Southampton Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases
AU2003295471B2 (en) 2002-11-15 2011-08-25 Genmab A/S Human monoclonal antibodies against CD25
JP4754219B2 (ja) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
CA2546017A1 (en) * 2003-11-26 2005-06-16 Health Research, Inc. Use of notch pathway interfering agents for treatment of plasma cell disorders
UA90480C2 (uk) 2004-07-22 2010-05-11 Джэнэнтэк, Инк. Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
AT502055B1 (de) 2005-06-21 2007-11-15 Univ Wien Med Anti tumor medikament
US20080241150A1 (en) 2006-05-15 2008-10-02 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1
EP2099827B1 (en) 2006-12-18 2018-11-21 Genentech, Inc. Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7834154B2 (en) 2007-02-09 2010-11-16 Genentech, Inc. Anti-ROBO4 antibodies and uses therefor
WO2008140826A1 (en) * 2007-05-15 2008-11-20 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
PL2187964T3 (pl) 2007-08-10 2015-03-31 Regeneron Pharma Ludzkie przeciwciała o wysokim powinowactwie przeciw ludzkiemu czynnikowi wzrostu nerwu
JP2009078998A (ja) * 2007-09-26 2009-04-16 Univ Of Tokushima Ｊａｇｇｅｄ２を用いる制癌剤
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
CN102264763B (zh) 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
MX2011002928A (es) 2008-10-01 2011-04-11 Genentech Inc Anticuerpos anti-notch2 y metodos de uso.
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US8945569B2 (en) * 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
US20130089562A1 (en) 2011-10-05 2013-04-11 Genenthech, Inc. Methods of treating liver conditions using notch2 antagonists
SG11201408554QA (en) 2012-06-22 2015-02-27 Cytomx Therapeutics Inc Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
RU2666990C2 (ru) 2012-08-13 2018-09-13 Дженентек, Инк. Антитела к jagged и способы их применения
MX2015011444A (es) 2013-03-15 2015-12-16 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
SI3105253T1 (sl) 2014-02-12 2018-10-30 F. Hoffmann-La Roche Ag Protitelesa anti-Jagged1 in načini njihove uporabe
EP3166627A1 (en) * 2014-07-11 2017-05-17 Genentech, Inc. Notch pathway inhibition

Similar Documents

Publication Publication Date Title
JP2017536102A5 (enExample)
RU2017119543A (ru) Анти-tim3 антитела и способы их применения
HRP20200767T1 (hr) Humanizirana anti-humana cd19 protutijela i postupci uporabe
HRP20221141T1 (hr) Anti-lag3 protutijela
JP2020500538A5 (enExample)
JP2013538553A5 (enExample)
RU2013102225A (ru) АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2016502515A5 (enExample)
JP2015533795A5 (enExample)
JP2014158469A5 (enExample)
FI3137504T3 (fi) Fcrn:ään sitoutuva vasta-aine autoimmuunisairauksien hoitamista varten
RU2021114500A (ru) НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ
RU2015108797A (ru) Антитела к jagged и способы их применения перекрестная ссылка на родственные заявки
JP2018527919A5 (enExample)
RU2016129517A (ru) Биспецифические антитела к her2 и способы применения
RU2013143358A (ru) Анти-fgfr4 антитела и способы их применения
JP2017534259A5 (enExample)
JP2017514461A5 (enExample)
JP2014502955A5 (enExample)
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
RU2011142281A (ru) Антитела к her
RU2014109093A (ru) Антитела против нейрегулина и их применение
JP2016512551A5 (enExample)
JP2015500207A5 (enExample)
RU2015102069A (ru) Антитела к биотину и способы их применения